Core Points - Netcompany has updated its long-term financial targets ahead of the Interim Report Q3 2025 release on 30 October 2025 [1] - A detailed discussion on strategic initiatives and financial targets will take place during the Capital Markets Day on 31 October 2025 [1] Financial Targets - The company aims for long-term organic revenue growth of between 5% and 10% through any business cycle [3] - An adjusted EBITDA margin above 20% is targeted to be achieved by 2029 [3] - Dynamic cash redistribution will be implemented through share buyback programs and dividends of all free cash flow before any acquisitions, while adhering to leverage targets [3] - The completion of a DKK 2 billion share buyback program is expected by 2026, as originally introduced in 2023 [3] - The company aims to maintain a leverage ratio below 1x [3]

Core Viewpoint - Chijet Motor Company, Inc. will implement a 100-for-1 share consolidation of its ordinary shares effective November 3, 2025, which aims to increase the market price per share [1][5]. Share Consolidation Details - The shareholders approved the share consolidation at the annual general meeting on September 24, 2025, allowing for the consolidation of class A and class B ordinary shares [2]. - The consolidation will convert every 100 class A ordinary shares with a par value of US$0.003 into one class A ordinary share with a par value of US$0.3, and similarly for class B shares [2]. - The exact consolidation ratio will be determined by the board of directors within the approved range [2]. Trading and Administrative Aspects - The class A ordinary shares will begin trading on a consolidation-adjusted basis on the Nasdaq Capital Market starting November 3, 2025, with a new CUSIP number assigned [3]. - The share consolidation will affect all issued and outstanding ordinary shares uniformly, and no action is required from shareholders holding shares in book-entry form or through brokers [4][6]. Company Overview - Chijet Motor Company focuses on the development, manufacture, sales, and service of traditional fuel vehicles and new energy vehicles (NEVs) [7]. - The company operates a large modern vehicle production base in Jilin, China, and is constructing a factory in Yantai, China, dedicated to NEV production [7]. - The management team comprises industry veterans with extensive experience in various fields including engineering, design, and financial management [7].

Company Announcement No 52/2025Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk29 October 2025 Sydbank, Arbejdernes Landsbank and Vestjysk Bank publish merger documents On 27 October 2025 Sydbank A/S (“Sydbank”), Aktieselskabet Arbejdernes Landsbank (“Arbejdernes Landsbank”) and Vestjysk Bank A/S (“Vestjysk Bank”) announced that they have entered into an agreement to merge the three banks (“the Merger”). Reference is made to Sydbank’s C ...

ATHENS, Greece, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Star Bulk Carriers Corp. (the "Company" or "Star Bulk") (Nasdaq: SBLK), a global leader in dry bulk shipping, today announced the publication of its 2024 Environmental, Social and Governance (ESG) Report. The 2024 ESG Report — Star Bulk’s seventh annual publication — provides a comprehensive overview of the Company’s sustainability strategy, performance, and future goals. Guided by its ESG Committee, Star Bulk continues to innovate and embed best practices a ...

AI and skill integration are enhancing the performance management processNEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- WTW (NASDAQ:WTW), a leading global advisory, broking and solutions company, found that almost half of organizations believe performance management optimization would significantly increase productivity, yet most programs lack clarity and effectiveness. The study also found that more organizations are using AI and integrating skills as part of their performance management process. According to ...

Core Insights - The company reported strong growth in revenue and EBITDA for the first nine months of 2025, with operating revenue reaching ISK 9,296 million, a 9.2% increase year-on-year [4][5] - The company has updated its outlook for 2025, expecting operating revenues between ISK 12,360 and 12,610 million, with rental income estimated between ISK 10,650 and 10,870 million [13][14] Financial Performance - Operating revenue for the first nine months was ISK 9,296 million, with rental income contributing ISK 7,980 million, reflecting a real growth of 5.1% year-on-year [4] - EBITDA for the period was ISK 5,968 million, marking a 7.8% increase compared to the previous year [5] - Profit before income tax was ISK 4,755 million, and total profit for the period was ISK 3,804 million [5] - The Net Operating Income (NOI) ratio was 72.6%, slightly down from 73.4% in the same period of 2024 [6] Balance Sheet Overview - Total assets amounted to ISK 163,349 million, with investment properties valued at ISK 152,811 million [7] - The company's equity was ISK 53,071 million, resulting in an equity ratio of 32.5% [7] - Total liabilities were ISK 110,278 million, with interest-bearing liabilities at ISK 88,360 million [8] - The loan-to-value ratio was 55.7% at the end of the period [9] Real Estate Portfolio - The company signed a purchase agreement for all shares in Festing hf., which includes properties totaling approximately 43,000 square meters [10] - The occupancy rate improved to 95.6%, an increase of 2.0 percentage points from the beginning of the year [11] - The company signed lease agreements for nearly 30,500 square meters during the first nine months [12] Updated Outlook - The company expects a 2025 occupancy rate between 94-95% and anticipates annual rental income to increase by ISK 470 - 510 million once the target occupancy is achieved [15][16] - The updated outlook does not include income or expenses from Festing hf.'s properties for 2025 [14] Organizational Changes - A new organizational structure was announced to enhance customer service and streamline communication, reducing the executive management team from seven to four members [17]

Core Insights - Telitacicept has shown significant improvement in quality of life for patients with generalized myasthenia gravis (gMG), with 100% of patients achieving a ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) after 48 weeks [1][2] - The drug demonstrated sustained efficacy and a favorable safety profile, suggesting it may have a global best-in-disease profile for gMG [1][2] Study Results - In the 48-week open-label extension (OLE) study, patients on telitacicept achieved a mean reduction of -7.5 points in MG-ADL, while those who crossed over from placebo achieved a -6.3 point reduction [6] - At week 48, 96.2% of continuous telitacicept patients and 90.2% of crossover patients reached a ≥3-point improvement in MG-ADL [6] - The mean change in Quantitative Myasthenia Gravis (QMG) was -9.8 for continuous patients and -9.3 for crossover patients, with 94.2% and 90.2% achieving a ≥5-point improvement, respectively [6] Mechanism of Action - Telitacicept is a recombinant fusion protein that selectively inhibits BLyS (BAFF) and APRIL, two cytokines crucial for B cell and plasma cell survival, thereby reducing autoreactive B cells and autoantibody production [5] Regulatory Status - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [7] - A global Phase 3 clinical trial for gMG is currently ongoing across 14 countries, aiming for potential approval in the United States, Europe, and Japan [7] Disease Context - Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disorder affecting approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan, characterized by muscle weakness due to autoantibodies [8]

Core Insights - Argenx SE presented new data on the efficacy and safety of VYVGART for generalized myasthenia gravis (gMG) at the 2025 AANEM and MGFA meetings, highlighting its potential to improve patient outcomes across various gMG populations [1][2][3] Efficacy and Safety Data - The pivotal Phase 3 ADAPT SERON trial demonstrated that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant improvement in MG-ADL total score compared to placebo, with a mean change of 3.35 points at week 4 [6] - Approximately 60% of VYVGART-treated gMG patients achieved minimal symptom expression (MSE), with 88% sustaining MSE for at least 4 weeks [5][6] - Real-world data indicated that over 70% of patients treated with VYVGART significantly reduced glucocorticoid use while maintaining clinical benefits [5][15] Treatment Impact - VYVGART is positioned as a targeted, effective, and safe treatment for gMG patients, regardless of autoantibody status, with ongoing studies contributing to redefining treatment standards [4][7] - The ADAPT Jr study showed that VYVGART improved outcomes in adolescents with gMG, addressing a high unmet need in this population [8] Regulatory Plans - Argenx plans to share the ADAPT SERON trial results with the U.S. FDA to seek an expansion of the VYVGART label to include adult AChR-Ab seronegative gMG patients across all subtypes [7] Long-term Outcomes - Long-term treatment with VYVGART was associated with substantial reductions in oral glucocorticoid use, with 72.5% of patients achieving meaningful tapering and an average daily dose reduction of over 50% after 18 months [15][26]

ROBESONIA, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Blaqclouds Inc. (OTC: BCDS), a leading Web3 infrastructure company, today announced the official launch of Deploy Launchpad, a full-suite, multi-chain token launch and ecosystem acceleration platform designed to empower developers, innovators, and organizations across the decentralized economy. Built to simplify the path from concept to capital, Deploy Launchpad integrates directly with Apollo Wallet and supports over 20 blockchains, including Ethereum (ETH) ...

Core Insights - AlphaTON Capital plans to invest significantly in GPU and data center resources to support the launch of Cocoon, a decentralized AI infrastructure announced by Telegram founder Pavel Durov [1][2][3] - Cocoon aims to provide secure and private AI inference through a distributed network, where developers will compensate GPU owners with TON cryptocurrency for processing requests [2][4] - The launch of Cocoon is seen as a pivotal moment in the integration of blockchain technology, data protection, and artificial intelligence [3][4] Company Strategy - AlphaTON Capital is committed to becoming a key contributor to the Cocoon ecosystem by deploying enterprise-grade GPU infrastructure to ensure sufficient computational capacity for major applications [3][4] - The company will utilize next-generation high-memory GPU models optimized for AI workloads across strategically located data centers, focusing on reliability and processing capacity [3][4] - AlphaTON Capital's participation highlights its strategic focus on the TON blockchain and Telegram-based AI applications, with the Cocoon network set to launch in November 2025 [4] Market Position - The Cocoon network is positioned to address a critical market need for privacy and security in AI, with AlphaTON Capital uniquely positioned as both a participant in the TON ecosystem and an infrastructure provider [4][6] - The company aims to provide institutional-grade exposure to the TON ecosystem and Telegram's extensive user base, leveraging its treasury strategy that includes direct token acquisition and strategic investments [6][7]